Return to search results.
Complete title: A Phase 1/2 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies
|Research Study Number||2724.00|
|Principal Investigator||Damian Green, MD|
Research Study Description
- To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984
- To characterize the global safety profile including cumulative toxicities
- To evaluate the pharmacokinetic (PK) profile of SAR650984 in the proposed dosing schedule(s)
- To assess the pharmacodynamics, immune response, and preliminary disease response
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Hematologic Malignancies; Immunotherapy
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.